138 related articles for article (PubMed ID: 17596950)
1. Estimation of hERG inhibition of drug candidates using multivariate property and pharmacophore SAR.
Johnson SR; Yue H; Conder ML; Shi H; Doweyko AM; Lloyd J; Levesque P
Bioorg Med Chem; 2007 Sep; 15(18):6182-92. PubMed ID: 17596950
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of an in silico model for hERG binding.
Song M; Clark M
J Chem Inf Model; 2006; 46(1):392-400. PubMed ID: 16426073
[TBL] [Abstract][Full Text] [Related]
3. A QSAR model of HERG binding using a large, diverse, and internally consistent training set.
Seierstad M; Agrafiotis DK
Chem Biol Drug Des; 2006 Apr; 67(4):284-96. PubMed ID: 16629826
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
[TBL] [Abstract][Full Text] [Related]
5. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
Aronov AM
J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
[TBL] [Abstract][Full Text] [Related]
6. A composite model for HERG blockade.
Kramer C; Beck B; Kriegl JM; Clark T
ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
[TBL] [Abstract][Full Text] [Related]
7. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
[TBL] [Abstract][Full Text] [Related]
8. In silico prediction of hERG inhibition.
Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
[TBL] [Abstract][Full Text] [Related]
9. A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability.
Leong MK
Chem Res Toxicol; 2007 Feb; 20(2):217-26. PubMed ID: 17261034
[TBL] [Abstract][Full Text] [Related]
10. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Hancox JC; McPate MJ; El Harchi A; Zhang YH
Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
[TBL] [Abstract][Full Text] [Related]
11. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
Guthrie H; Livingston FS; Gubler U; Garippa R
J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
[TBL] [Abstract][Full Text] [Related]
12. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
13. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools.
Moorthy NS; Ramos MJ; Fernandes PA
J Enzyme Inhib Med Chem; 2014 Jun; 29(3):317-24. PubMed ID: 23560722
[TBL] [Abstract][Full Text] [Related]
14. Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds.
Moorthy NS; Ramos MJ; Fernandes PA
SAR QSAR Environ Res; 2012 Jul; 23(5-6):521-36. PubMed ID: 22452318
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656.
Ridley JM; Milnes JT; Duncan RS; McPate MJ; James AF; Witchel HJ; Hancox JC
FEBS Lett; 2006 Apr; 580(8):1999-2005. PubMed ID: 16542653
[TBL] [Abstract][Full Text] [Related]
16. Prediction of hERG Liability - Using SVM Classification, Bootstrapping and Jackknifing.
Sun H; Huang R; Xia M; Shahane S; Southall N; Wang Y
Mol Inform; 2017 Apr; 36(4):. PubMed ID: 28000393
[TBL] [Abstract][Full Text] [Related]
17. QSAR modeling and data mining link Torsades de Pointes risk to the interplay of extent of metabolism, active transport, and HERG liability.
Broccatelli F; Mannhold R; Moriconi A; Giuli S; Carosati E
Mol Pharm; 2012 Aug; 9(8):2290-301. PubMed ID: 22742658
[TBL] [Abstract][Full Text] [Related]
18. Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data.
Gavaghan CL; Arnby CH; Blomberg N; Strandlund G; Boyer S
J Comput Aided Mol Des; 2007 Apr; 21(4):189-206. PubMed ID: 17384921
[TBL] [Abstract][Full Text] [Related]
19. Effects of fluoroquinolones on HERG channels and on pancreatic beta-cell ATP-sensitive K+ channels.
Zünkler BJ; Claassen S; Wos-Maganga M; Rustenbeck I; Holzgrabe U
Toxicology; 2006 Dec; 228(2-3):239-48. PubMed ID: 17027138
[TBL] [Abstract][Full Text] [Related]
20. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
Ridley JM; Milnes JT; Hancox JC; Witchel HJ
J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]